Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

NAUnknownINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 30, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2020

Conditions
Non-Small-Cell Lung
Interventions
DRUG

Anlotinib Hydrochloride

Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle

DRUG

Gefitinib

Tablet, P.O. 250mg qd

DRUG

Icotinib

Tablet, P.O. 125mg tid

Trial Locations (1)

Unknown

The First Affiliated hospital of soochow university, Suzhou

All Listed Sponsors
collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

Second Affiliated Hospital of Soochow University

OTHER

collaborator

Nantong University

OTHER

collaborator

Affiliated Hospital of Jiangnan University

OTHER

collaborator

Jiangyin People's Hospital

OTHER

collaborator

Changzhou No.2 People's Hospital

OTHER

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER